COMP <GO>
ACHC vs VCYT // FREE CASH FLOW YIELD
Acadia Healthcare Company Inc. (NASDAQ) VS. Veracyte Inc. (NASDAQ) • 15-METRIC TALLY: ACHC 1
— VCYT 10
▲ FREE CASH FLOW YIELD LEADER: VCYT
LAST: $29.46 (-0.17%) • MKT CAP: $2.74B
fcf-yield
-16.04%
LAST: $52.17 (+3.70%) • MKT CAP: $4.19B
fcf-yield
3.02%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACHC VS. VCYT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACHC | VCYT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.10% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -24.80% | 4.60% | -29.40 | VCYT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 58.7x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -16.04% | 3.02% | -19.06 | VCYT | /fcf-yield <GO> |
| Operating Margin | -40.60% | 11.20% | -51.80 | VCYT | /operating-margins <GO> |
| Net Profit Margin | -33.30% | 12.80% | -46.10 | VCYT | /net-margins <GO> |
| Revenue Growth (YoY) | 5.00% | 16.00% | -11.00 | VCYT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 26.00 | -25.55 | VCYT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | VCYT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.3 | 65.5 | -18.20 | VCYT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 1.08 | -0.01 | VCYT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 53.1x | -32.10 | ACHC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.74B | $4.19B | -$1.45B | VCYT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACHC REV | VCYT REV | ACHC GROSS % | VCYT GROSS % | ACHC FCF | VCYT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.31B | $517.1M | — | 70.1% | -$439.9M | $126.6M |
| FY 2024 | $3.15B | $445.8M | — | 66.9% | -$560.7M | $63.8M |
| FY 2023 | $2.93B | $361.1M | — | — | $330.5M | $28.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACHC // BETA 1.07
VCYT // BETA 1.08